![]() ![]() The MGuard™ Embolic Protection Stent (EPS) is a novel device. 2 Even if aspiration is good, embolisation remains an ongoing issue. However, the Thrombus Aspiration during ST-segment Elevation myocardial infarction (TASTE) study (n= 7244) found that routine thrombus aspiration before PCI as compared with PCI alone did not result in a reduction in 30-day mortality. 1 Results showed a reduction in all-cause mortality at 30 days. The Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS), prospective randomised trial, aimed to determine whether aspiration of thrombotic material before stent implantation of the infarct-related coronary artery resulted in improved myocardial perfusion compared with conventional primary PCI. Therapeutic Alternatives for Intracoronary Thrombus – MASTER Results in Perspectiveĭr Abizaid began by emphasising the need for therapeutic alternatives to avoid distal thromboembolism (embolisation) during highly thrombotic situations such as STEMI. These presentations aimed to discuss the importance of thrombus management in PCI for STEMI patients, to give an update of relevant clinical data on the performance of the MGuard™ stent in STEMI patients and to present real life examples on how this device selection can influence the outcome in STEMI patients. A symposium was sponsored by Inspire MD and chaired by Alexandre Abizaid, Institute Dante Pazzanese de Cardiologia (Sao Paulo, Brazil), and Jean Fajadet, Clinique Patteur, (Toulouse, France). Unfortunately, there is a lack of significant adjunctive devices to protect the microcirculation. This may lead to distal vessel occlusion resulting in impaired myocardial perfusion, which is associated with larger infarct size, incomplete ST resolution and increased mortality. This report of the proceedings of a symposium at EuroPCR, 20–, Paris, France, discussed clinical trial data, as well as a number of clinical cases, illustrating the utility of the MGuard EPS in difficult situations.Įmbolisation of atherothrombotic material is a common occurrence during percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI). Data from the andomised Safety and Efficacy Study of MGuard Stent After a Heart Attack (MASTER II) trial and from a real-life registry have shown the efficacy and safety of the MGuard in primary PCI. When used in acute STEMI, the MGuard EPS shows significant improvement in myocardial flow and ST resolution, even in complicated clinical cases vs the standard approach with conventional bare metal or drug-eluting stents. The MGuard™ embolic protection stent (EPS) features a unique polymer micronet mesh coating. This causes microvascular occlusions, leading to a further reduction in myocardial reperfusion. doi: 10.1002/ embolisation of atherothrombotic material is a frequent consequence of percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI). A prospective, postmarket study with the MGuard Prime embolic protection stent in ST-segment elevation myocardial infarction: the International MGuard Prime Observational Study (IMOS Prime). ![]() 2015 8(9):1229–34.Īmoroso G, Vos NS, Van der Heyden JA, van der Schaaf RJ, Patterson MS, Vink MA, et al. A prospective, multicenter study of a novel mesh-covered carotid stent: the CGuard CARENET trial (Carotid Embolic Protection Using MicroNet). Joachim S, Piotr M, Klaudija B, Ralf K, Mariusz T, Zbigniew S, et al. Real world comparison of the MGuard stent versus the bare metal stent for ST elevation myocardial infarction (the REWARD-MI study). 2014.įernández-Cisnal A, Cid-Álvarez B, Álvarez- Álvarez B, Cubero-Gomez JM, Ocaranza-Sanchez R, Lopez-Otero D, et al. MGuard Prime Voluntary Field Safety Corrective Action Report. MGuard ® stent retrieval after failed implantation and withdrawal. Lopez-Minguez JR, Nogales-Asensio JM, Gonzalez-Fernandez R. Prospective, randomized, multicenter evaluation of a polyethylene terephthalate micronet mesh-covered stent (MGuard) in ST-segment elevation myocardial infarction: The MASTER Trial. Stone GW, Abizaid A, Silber S, Dizon JM, Merkley B, Costa RA, et al. ![]()
0 Comments
Leave a Reply. |